Back to Webinars
Webinars

Comparison of multiplexed platforms for serum cytokine detection in COVID-19 patients

Online
Topic:
VIEW ON DEMAND

Speaker

  • Holden Maecker, PhD
    Professor (Research), Microbiology & Immunology
    Stanford University
  • Alex Forrest-Hay
    VP of Sales
    Alamar Biosciences

Summary

Alamar NULISAseq is a novel commercial platform for highly multiplexed analysis of soluble proteins using a modified proximity ligation assay. We compared Luminex, Olink, and NULISAseq platforms for detection of cytokines and related inflammatory markers in sera from 25 patients with COVID-19 and 8 healthy controls. We analyzed detectability of common targets, correlations between platforms, and identification of differentially expressed targets in COVID-19 patients (versus healthy controls, over time, and with disease severity). We found the highest proportion of detectable targets with NULISAseq, and best correlations between NULISAseq and Olink. Correlations were often better for targets with high detectability. NULISAseq also identified the largest number of significant changes over time in longitudinal COVID-19 samples. Olink identified slightly more differentially expressed targets between healthy and COVID-19 samples, but some of these were, paradoxically, low in detectability in Olink. All three assays were similar in their ability to differentiate COVID-19 severity levels at hospital admission. Overall, our results suggest that NULISAseq is a highly sensitive assay, with good correlation
Learning Objectives
  • To understand the methodology used by major multiplexed immunoassay platforms, and the inherent pros and cons of each.
  • To describe the differences in detectability between assay platforms and how this relates to correlations between platforms.
  • To relate these assay differences to their ability to detect differential protein expression in COVID-19 patients.
VIEW ON DEMAND
Linkedin

Steve Williams, MD, PhD

CSO

Dr. Willams serves as the company’s Chief Scientific Officer. He was previously Chief Medical Officer at Standard Biotools and at SomaLogic where he pioneered the discipline for discovery and validation of predictive, diagnostic and prognostic models using machine-learning applied to large-plex proteomics. 20 such tests were used for drug characterization, safety and efficacy when incorporated in clinical drug trials at Pharma/Biotech and 17 different multivariate tests were validated and translated into regulated healthcare uses. Prior to SomaLogic, Dr. Williams was at Pfizer in the UK and the USA as a clinical triallist in Translational Medicine, and subsequently as VP, Global Clinical Technology. He sat on the National Advisory Council for the National Institute of Biomedical Imaging and Bioengineering, the Executive Committee for the FNIH Biomarkers Consortium, and worked with FDA and PhRMA on developing evidentiary standards for biomarker qualification. Dr. William’s medical training was in London, at Charing Cross and Westminster Medical School, followed by a PhD in medicine/physiology at the same institution and training in Radiology at the University of Newcastle Upon Tyne. Steve is co-inventor on 26 proteomics patents and author/coauthor on multiple foundational proteomics manuscripts.

Linkedin

Justin McAnear

CFO

Mr. McAnear serves as the company’s Chief Financial Officer. He brings over 25 years of operational and financial leadership experience across various sectors and was instrumental in taking 10x Genomics public in 2019, serving as its CFO for over five years. Mr. McAnear served for over 3 years as Tesla’s VP of Worldwide Finance and Operations, supporting landmark initiatives such as the Model X and Model 3 launches and Solar City acquisition.  He also held various roles at Apple and J&J earlier in his career and served as a naval officer and aviator for over 9 years.